Every DEF 14A that Jaguar Health, Inc. (JAGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow JAGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAGX filings page.
Jaguar Health, Inc. has called a special stockholder meeting for September 4, 2026 to approve several capital structure and equity proposals. Stockholders of record on July 6, 2026, holding 4,857,211 shares of Common Stock and 889.28 shares of Series Q Preferred Stock, may vote subject to a 9.99% voting cap on Series Q.
Proposal 1 seeks Nasdaq Rule 5635(d) approval to issue Common Stock upon exchange of Series Q Preferred Stock, which at an assumed $2.50 exchange price could result in up to 7,911,743 new shares, about 62.0% of pre-transaction Common Stock. Proposal 2 would reprice Investor Warrants on 60,781 shares to $1.00 and, together with 682,661 Series O dividend shares, permit issuance of up to 745,354 shares, about 13.3% of current Common Stock. Proposal 3 would amend the 2014 Stock Incentive Plan so the pool equals 14% of fully diluted shares as of September 30, 2026, versus 10,591 shares currently available (about 0.17% fully diluted). Proposal 4 would allow adjournment to seek additional proxies. The board unanimously recommends voting FOR all four proposals.
Jaguar Health has called its 2026 annual stockholder meeting for May 22, 2026 to elect one Class II director, ratify RBSM LLP as auditor, and vote on several financing proposals.
The company is seeking approval under Nasdaq Listing Rule 5635(d) to issue more than 19.99% of its common stock to C/M Capital Master Fund through a proposed $40 million equity line of credit and a separate preferred stock financing. Jaguar plans an equity line allowing sales of common stock up to $40 million plus 2% in commitment shares, and a private placement of Series P Non-Convertible Preferred Stock with $2.4 million stated value sold for $2.0 million, along with $72,000 of commencement shares. Both structures could significantly dilute existing holders if fully utilized, though C/M Capital’s ownership would be capped at 4.99%, or 9.99% with notice.
Jaguar Health has called a special stockholder meeting to reshape its capital structure. Stockholders will vote on raising authorized voting common shares from 298,000,000 to 500,000,000, increasing total authorized shares to 554,475,074. As of March 2, 2026, 12,419,277 common shares were outstanding.
The board is also seeking authority for two separate reverse stock splits, each at a ratio between 1‑for‑15 and 1‑for‑150, which together could reach an aggregate ratio of up to 1‑for‑22,500 if both are implemented. The board would choose exact ratios and timing within one year of approval for each split.
Another key proposal asks approval, under Nasdaq Listing Rule 5635(d), for issuing common shares upon exchange of a secured promissory note originally totaling $10,810,000 held by Streeterville Capital, LLC. Full exchange of the outstanding balance as of March 12, 2026 could exceed the current share count, meaning substantial potential dilution for existing holders. The board also seeks authority to adjourn the meeting if more time is needed to secure votes.
Jaguar Health (JAGX) called a Special Meeting for December 8, 2025 to seek stockholder approval under Nasdaq Rule 5635(d) for two financing-related items and a potential adjournment. Proposal 1 asks to approve issuing Common Stock upon exchange and/or redemption of 950.8 shares of Series N Preferred Stock. Based on a $2,500 stated value and a $1.20 exchange price, up to 1,980,827 Exchange Shares (or 1,980,833 Forced Redemption Shares) could be issued, which the company notes would have exceeded 20% of shares outstanding before issuance.
Proposal 2 seeks approval for the September 2025 private placement: 161,583 New PIPE Shares at $1.56 per share and a Pre-Funded PIPE Warrant for up to 479,442 shares (exercise price effectively $1.5599) with a Beneficial Ownership Limitation of 4.99% (increasable to 19.99%). As of October 31, 2025, 3,735,835 Common shares were outstanding. The company highlights potential dilution from issuances tied to Series N exchanges/redemptions and the PIPE, and seeks Proposal 3 authority to adjourn if more time is needed to solicit votes.